title: Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients.
abstract: The majority of children with Down syndrome (DS) tend to have frequent bacterial infections including recurrent respiratory infections. Our objective was to evaluate the production of antibodies to pneumococcal polysaccharide antigens after active immunization in DS subjects. IgG antibodies to pneumococcal serotypes (1, 3, 6B, 9V, and 14) were measured before and 6 weeks after immunization with a 23-valent pneumococcal vaccine (Pneumo23, Pasteur-Merrieux) in 6- to 13-year-old DS children (N = 17) and in aged-matched normal controls (N = 30). An adequate response was defined as a 4-fold increase over baseline or a post-immunization level of specific pneumococcal serotype antibody > or = 1.3 microg/mL. After immunization, all DS children had an increase in post-immunization levels against all serotypes analyzed. A 4-fold or more increase was observed in all DS children concerning serotypes 1 and 14, in 90% of subjects for serotypes 3 and 9V, and in 65% for serotype 6B. Regarding this increase, 8 of the 17 DS children had an adequate response to all serotypes analyzed, 8/17 patients to 4 serotypes and 1/17 to 3 serotypes. However, when we compared post-immunization levels between DS children and controls, we observed lower levels in the former group (P < 0.05) for all serotypes except serotype 3. We conclude that pneumococcal polysaccharide immunization could be beneficial for these DS children.
authors.affiliation: Disciplina de Alergia, Imunologia Clínica e Reumatologia, Departamento de Pediatria, Escola Paulista de Medicina, Universidade Federal de São Paulo, 04509-001 São Paulo, SP, Brazil. beacarvalho@terra.com.br
authors.forename: B T
authors.initials: BT
authors.lastname: Costa-Carvalho
authors.forename: R M A
authors.initials: RM
authors.lastname: Martinez
authors.forename: A T N
authors.initials: AT
authors.lastname: Dias
authors.forename: C A
authors.initials: CA
authors.lastname: Kubo
authors.forename: P
authors.initials: P
authors.lastname: Barros-Nunes
authors.forename: L
authors.initials: L
authors.lastname: Leiva
authors.forename: D
authors.initials: D
authors.lastname: Solé
authors.forename: M M S
authors.initials: MM
authors.lastname: Carneiro-Sampaio
authors.forename: C K
authors.initials: CK
authors.lastname: Naspitz
authors.forename: R U
authors.initials: RU
authors.lastname: Sorensen
mesh_terms: D000293:Adolescent; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology*; D016022:Case-Control Studies; D002648:Child; D004314:Down Syndrome / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology*; D008297:Male; D011008:Pneumococcal Infections / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000276:immunology*
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines